Nkarta price target raised to $22 from $10 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Nkarta to $22 from $10 and keeps a Buy rating on the shares. NKX019 demonstrated elimination of CD19+ cells from circulation, suggesting B cell aplasia, the analyst tells investors in a research note.